Trial Outcomes & Findings for Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer (NCT NCT00750555)
NCT ID: NCT00750555
Last Updated: 2019-02-26
Results Overview
Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data table.
TERMINATED
PHASE2
4 participants
1 year
2019-02-26
Participant Flow
After the enrollment of 4 participants in this study, the PI left Geisinger. Geisinger does not have any details regarding which Arm/Group participants were assigned to.
Participant milestones
| Measure |
One Year Disease Free
Erlotinib: 150 mg per day orally until disease progression occurs, up to a maximum of 12 months
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 1 yearPopulation: Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data tables.
Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data table.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 2 yearsPopulation: Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data tables.
Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data tables.
Outcome measures
Outcome data not reported
Adverse Events
One Year Disease Free
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place